<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064844</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAACOO11197-05</org_study_id>
    <secondary_id>R01AA011197</secondary_id>
    <nct_id>NCT00064844</nct_id>
  </id_info>
  <brief_title>Combination Nicotine Replacement for Alcoholic Smokers</brief_title>
  <official_title>Combination Nicotine Replacement for Alcoholic Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the study is to develop recommendations for treatment programs to
      help alcoholic smokers to stop smoking. A sample of 175 alcohol dependent cigarette smokers
      will be recruited from the community and treated in a 6-month outpatient alcohol and tobacco
      treatment program. The 175 patients will be divided into two groups. One group will receive
      an active nicotine patch and active nicotine gum. The other group will receive an active
      nicotine patch and placebo nicotine gum. Followup assessments will be conducted for 1-year
      from the beginning of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 Month Smoking Abstinence</measure>
    <time_frame>6 months after smoking quit date</time_frame>
    <description>Percentage of participants with prolonged carbon monoxide verified smoking abstinence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12 Month Smoking Abstinence</measure>
    <time_frame>12 months after smoking quit date</time_frame>
    <description>Percentage of participants with prolonged carbon monoxide verified smoking abstinence</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Smoking</condition>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Nicotine patch plus placebo gum</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy. Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine patch plus active gum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy. Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavior Therapy for alcohol and smoking cessation</intervention_name>
    <description>Individual 60-minute treatment sessions were scheduled weekly for the first 3 months, then monthly for the next 3 months for a total of 16 sessions. Alcohol treatment was based on the cognitive behavioral therapy manual developed for Project MATCH, with approximately 40-45 minutes of each session devoted to alcohol treatment. Components of this intervention included identifying alcohol antecedents, coping with alcohol urges, managing thoughts about alcohol, problem solving, drink refusal skills, planning for emergencies, communication and assertiveness training and enhancing social support networks for alcohol abstinence. The smoking cessation intervention was delivered in the same sessions as the alcohol treatment, with approximately 15-20 minutes of each session devoted to smoking cessation. Treatment employed behavioral elements that have been supported empirically according to the USDHHS smoking cessation practice guideline.</description>
    <arm_group_label>Nicotine patch plus placebo gum</arm_group_label>
    <arm_group_label>Nicotine patch plus active gum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Males and females at least 18 years old.

          -  English speaking.

          -  Meets criteria for alcohol dependence or alcohol abuse.

          -  Must complete an alcohol detoxification program prior to entering the study.

          -  Currently smoking 15 or more cigarettes per day and have at least a 3 year history of
             smoking.

          -  Have a current desire to stop smoking and stop drinking.

          -  Willing to complete followup assessments up to 12 months after treatment.

          -  Willing to provide names of 2 people who can help locate the subject at followup and
             the name of one person who can verify information about alcohol and tobacco use.

          -  One person per household.

        Exclusion Criteria:

          -  Allergy to nicotine patch or nicotine gum.

          -  Weigh less than 100 pounds.

          -  Use other nicotine products, such as cigars, pipes or smokeless tobacco.

          -  Severe skin disorder.

          -  Active peptic ulcer.

          -  Active joint disease.

          -  Heart attack within 3 months prior to entering the study.

          -  Pregnant or breastfeeding female who are not on birth control.

          -  Currently taking medication to treat alcoholism or smoking, such as naltrexone,
             disulfiram or bupropion.

          -  Poor vision or hearing that would interfere with using a cell phone.

          -  Lack of transportation to the treatment site or live at least one hour from the
             treatment site.

          -  Homeless.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ned Cooney, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System</name>
      <address>
        <city>Newington</city>
        <state>Connecticut</state>
        <zip>06111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cooney NL, Cooney JL, Perry BL, Carbone M, Cohen EH, Steinberg HR, Pilkey DT, Sevarino K, Oncken CA, Litt MD. Smoking cessation during alcohol treatment: a randomized trial of combination nicotine patch plus nicotine gum. Addiction. 2009 Sep;104(9):1588-96. doi: 10.1111/j.1360-0443.2009.02624.x. Epub 2009 Jun 22.</citation>
    <PMID>19549054</PMID>
  </reference>
  <reference>
    <citation>Holt LJ, Litt MD, Cooney NL. Prospective analysis of early lapse to drinking and smoking among individuals in concurrent alcohol and tobacco treatment. Psychol Addict Behav. 2012 Sep;26(3):561-72. doi: 10.1037/a0026039. Epub 2011 Oct 24.</citation>
    <PMID>22023022</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2003</study_first_submitted>
  <study_first_submitted_qc>July 14, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2003</study_first_posted>
  <results_first_submitted>January 31, 2013</results_first_submitted>
  <results_first_submitted_qc>March 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 16, 2013</results_first_posted>
  <last_update_submitted>March 8, 2013</last_update_submitted>
  <last_update_submitted_qc>March 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Ned Cooney</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Alcoholism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>96 men and women were randomized to treatment at the Newington and West Haven campuses of the Veterans Affairs (VA) Connecticut Healthcare System.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Nicotine Patch Plus Active Gum</title>
        </group>
        <group group_id="P2">
          <title>Nicotine Patch Plus Placebo Gum</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>2 Week Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3 Month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>12 Month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nicotine Patch Plus Active Gum</title>
        </group>
        <group group_id="B2">
          <title>Nicotine Patch Plus Placebo Gum</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.1" spread="10.2"/>
                    <measurement group_id="B2" value="44.8" spread="10.1"/>
                    <measurement group_id="B3" value="44.9" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>6 Month Smoking Abstinence</title>
        <description>Percentage of participants with prolonged carbon monoxide verified smoking abstinence</description>
        <time_frame>6 months after smoking quit date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Patch Plus Active Gum</title>
          </group>
          <group group_id="O2">
            <title>Nicotine Patch Plus Placebo Gum</title>
          </group>
        </group_list>
        <measure>
          <title>6 Month Smoking Abstinence</title>
          <description>Percentage of participants with prolonged carbon monoxide verified smoking abstinence</description>
          <units>percentage of participants abstinent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>12 Month Smoking Abstinence</title>
        <description>Percentage of participants with prolonged carbon monoxide verified smoking abstinence</description>
        <time_frame>12 months after smoking quit date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Patch Plus Active Gum</title>
          </group>
          <group group_id="O2">
            <title>Nicotine Patch Plus Placebo Gum</title>
          </group>
        </group_list>
        <measure>
          <title>12 Month Smoking Abstinence</title>
          <description>Percentage of participants with prolonged carbon monoxide verified smoking abstinence</description>
          <units>percentage of participants abstinent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Chi-squared</method>
            <method_desc>df = 1, N = 96</method_desc>
            <param_type>chi square</param_type>
            <param_value>7.25</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nicotine Patch Plus Active Gum</title>
        </group>
        <group group_id="E2">
          <title>Nicotine Patch Plus Placebo Gum</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>bleeding gums</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>jaw ache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ned Cooney, PhD</name_or_title>
      <organization>Yale University School of Medicine</organization>
      <phone>860-594-6339</phone>
      <email>ned.cooney@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

